Experimental estimates of the prevalence and duration of long COVID symptoms, and rates of adverse events for hospitalised coronavirus (COVID-19) patients compared with those for matched control patients.

As part of an ongoing partnership with the Census Bureau, the National Center for Health Statistics (NCHS) recently added questions to assess the prevalence of post-COVID-19 conditions (long COVID), on the experimental Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S. Data collection began on April 23, 2020. Beginning in Phase 3.5 (on June 1, 2022), NCHS included questions about the presence of symptoms of COVID that lasted three months or longer. Phase 3.5 will continue with a two-weeks on, two-weeks off collection and dissemination approach. Estimates on this page are derived from the Household Pulse Survey and show the percentage of adults aged 18 and over who a) as a proportion of the U.S. population, the percentage of adults who EVER experienced post-COVID conditions (long COVID). These adults had COVID and had some symptoms that lasted three months or longer; b) as a proportion of adults who said they ever had COVID, the percentage who EVER experienced post-COVID conditions; c) as a proportion of the U.S. population, the percentage of adults who are CURRENTLY experiencing post-COVID conditions. These adults had COVID, had long-term symptoms, and are still experiencing symptoms; d) as a proportion of adults who said they ever had COVID, the percentage who are CURRENTLY experiencing post-COVID conditions; and e) as a proportion of the U.S. population, the percentage of adults who said they ever had COVID.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and aut

In-depth analysis of Winter Coronavirus (COVID-19) Infection Study data looking at trends in self-reported symptoms of coronavirus (COVID-19), including ongoing symptoms and associated risk factors.

This dataset is not being updated as hospitals are no longer mandated to report COVID Hospitalizations to CDPH.

Data is from the California COVID-19 State Dashboard at https://covid19.ca.gov/state-dashboard/

Note: Hospitalization counts include all patients diagnosed with COVID-19 during their stay. This does not necessarily mean they were hospitalized because of COVID-19 complications or that they experienced COVID-19 symptoms.

Note: Cumulative totals are not available due to the fact that hospitals report the total number of patients each day (as opposed to new patients).

The greater Seattle Coronavirus Assessment Network (SCAN) study is a response to the novel coronavirus outbreak (COVID-19). Since March 23rd, 2020, SCAN has worked in collaboration with Public Health Seattle & King County to deliver and collect at-home COVID-19 tests. The SCAN study is focused on testing people who are experiencing symptoms of COVID-19, and is working to increase testing in underrepresented communities and populations. The SCAN dashboard provides geographic and demographic information from King County about who is ordering a test kit (individuals, contacts and groups) and may differ from the testing data which includes all final results (positive, negative and inconclusive). Reported positives and positivity rate are a combination of general SCAN enrollment and contact testing results, and are not representative of overall population frequency. There was a pause in testing from May 13th through June 9th, during which time SCAN worked with the FDA to update procedures and certifications. Data is updated daily, subject to change and may vary across other technical reports due to the specific analyses being performed.

COVID-19 Treatment Locator

This dataset displays pharmacies, clinics, and other locations with safe and effective COVID-19 medications. These medications require a prescription from a healthcare provider. Some locations, known as Test to Treat sites, give you the option to get tested, get assessed by a healthcare provider, and receive treatment – all in one visit. COVID-19 medications may be available at additional locations that are not shown in this dataset.

The locations displayed have either self-attested they have inventory of Paxlovid (nirmatrelvir packaged with ritonavir), Lagevrio (molnupiravir), or Veklury (Remdesivir) within at least the last two months and/or reported participation in the Paxlovid Patient Assistance Program. Sites that have not reported in the last two weeks display a notification, "Inventory has not been reported in the last 2 weeks. Please contact the provider to make sure the product is available." Outpatient COVID-19 medications may be available at additional locations not listed on this website.

All therapeutics identified in the locator not approved by the FDA must be used in alignment with the terms of the respective product’s Emergency Use Authorization. Visit COVID-19 Treatments and Therapeutics for more information on all treatment options.

This website identifies sites that have commercially purchased inventory of COVID-19 treatments and, in some cases, may identify sites that have remaining, no-cost U.S. government distributed supply. Some sites may charge for services not covered by insurance. Some sites may offer telehealth services. This website is intended for informational purposes only and does not serve as an endorsement or recommendation for use of any of the locations listed on the sites.

Clarification for DoD Facilities: Those individuals eligible for care in an MTF include Active Duty Service Members (ADSMs), covered beneficiaries enrolled in TRICARE Prime or Select, including TRICARE Reserve Select (TRS), TRICARE Retired Reserve (TRR) and TRICARE Young Adult (TYA) participants, TRICARE for Life beneficiaries, and individuals otherwise entitled by law to MTF care (e.g., regular retired members and their dependents who are not enrolled in TRICARE but who are otherwise eligible for MTF space-available care, certain foreign military members and their families registered in DEERS, and others).

This synthetic dataset is based on anonymised real primary care patient data extracted from the CPRD Aurum database. The dataset focuses on patients presenting to primary care with symptoms indicative of COVID-19.

This dataset shows daily confirmed and probable cases of COVID-19 in New York City by date of specimen collection. Total cases has been calculated as the sum of daily confirmed and probable cases. Seven-day averages of confirmed, probable, and total cases are also included in the dataset. A person is classified as a confirmed COVID-19 case if they test positive with a nucleic acid amplification test (NAAT, also known as a molecular test; e.g. a PCR test). A probable case is a person who meets the following criteria with no positive molecular test on record: a) test positive with an antigen test, b) have symptoms and an exposure to a confirmed COVID-19 case, or c) died and their cause of death is listed as COVID-19 or similar. As of June 9, 2021, people who meet the definition of a confirmed or probable COVID-19 case >90 days after a previous positive test (date of first positive test) or probable COVID-19 onset date will be counted as a new case. Prior to June 9, 2021, new cases were counted ≥365 days after the first date of specimen collection or clinical diagnosis. Any person with a residence outside of NYC is not included in counts. Data is sourced from electronic laboratory reporting from the New York State Electronic Clinical Laboratory Reporting System to the NYC Health Department. All identifying health information is excluded from the dataset.

These data are used to evaluate the overall number of confirmed and probable cases by day (seven day average) to track the trajectory of the pandemic. Cases are classified by the date that the case occurred. NYC COVID-19 data include people who live in NYC. Any person with a residence outside of NYC is not included.

This case surveillance publicly available dataset has 32 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors. This dataset requires a registration process and a data use agreement. CDC has three COVID-19 case surveillance datasets: COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements) COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements) COVID-19 Case Surveillance Restricted Access Data: Restricted access, patient-level dataset with clinical (including symptoms), demographics, and county and state of residence. Access requires a registration process and a data use agreement. (32 data elements) Requesting Access to the COVID-19 Case Surveillance Restricted Access Detailed Data Please review the following documents to determine your interest in accessing the COVID-19 Case Surveillance Restricted Access Detailed Data file: 1) CDC COVID-19 Case Surveillance Restricted Access Detailed Data: Summary, Guidance, Limitations Information, and Restricted Access Data Use Agreement Information 2) Data Dictionary for the COVID-19 Case Surveillance Restricted Access Detailed Data The next step is to complete the Registration Information and Data Use Restrictions Agreement (RIDURA). Once complete, CDC will review your agreement. After access is granted, Ask SRRG (eocevent394@cdc.gov) will email you information about how to access the data through GitHub. If you have questions about obtaining access, email eocevent394@cdc.gov. Overview The COVID-19 case surveillance database includes patient-level data reported by U.S. states and autonomous reporting entities, including New York City, the District of Columbia, as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification. The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and are shared voluntarily with CDC. For more information, visit: <a href="https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-c

All data relating to “Self-reported long COVID after infection with the Omicron variant in the UK".

These data show the number of skilled nursing facility residents and employees who were reported to DC Health as having any type of symptom or COVID-19 exposure that prompted a healthcare provider to order a test to determine if they had COVID-19; many of these people were tested when DC Health approval was required for ordering a test through the DC Public Health Laboratory. Resident and personnel loss of life that was associated with a positive SARS-CoV-2 test has been documented since mid-March 2020; DC Health relies on assisted living facilities to be forthcoming about this information in order for it to be properly documented in public reports. A resident is determined to be "cleared from isolation for COVID-19" if they are still alive and it has been at least 21 days since their initial symptom onset date or first positive specimen collection date for this COVID-19 infection.

This dataset includes long-term symptom prevalence data for 27 physical and mental health symptoms associated with Long COVID, extracted from 136 studies spanning up to three years. Key symptoms include fatigue, joint pain, myalgia, respiratory issues (dyspnea, cough), sensory impairments (anosmia, ageusia), neurological symptoms (brain fog), and mental health challenges (anxiety, depression, insomnia). This dataset provides critical insights into the evolving burden of Long COVID, supporting the development of personalized care strategies, targeted interventions, and informed public health policies.

DSH COVID-19 Patient Testing: Last updated -02/10/2025

DSH COVID-19 Patient Data reports on patient positives and testing counts at the facility level for DSH. The table reports on the following data fields:

• Total patients that tested positive for COVID-19 since 5/16/2020

• Patients newly positive for COVID-19 in the last 14 days

• Patient deaths while patient was positive for COVID-19 since 5/30/2020

• Total number of tests administered since 3/23/2020

Table Notes:

COVID-19 test results for patients include DSH patients who are tested while receiving treatment at an outside medical facility. Data has been de-identified in accordance with CalHHS Data De-identification Guidelines. Counts between 1-10 are masked with "<11". Includes Patients Under Investigation (PUIs) testing and proactive testing of asymptomatic patients for surveillance of geriatric, medically fragile, and skilled nursing facility units and for patients upon admission, re-admission, or discharge. Includes all individuals who were positive for COVID-19 at time of death, regardless of underlying health conditions or whether the cause of death has been confirmed to be COVID-19 related illness. Metro-Norwalk is additional COVID-19 surge space and technically a branch location that is part of DSH Metropolitan Hospital.

The COVID Symptom Tracker was designed by doctors and scientists at King's College London (KCL), Guys and St Thomas' Hospital working in partnership with ZOE Global. Led by Dr Tim Spector, professor of genetic epidemiology at KCL and director of TwinsUK.

The COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program provides reimbursements on a rolling basis directly to eligible health care entities for claims that are attributed to the testing, treatment, and or vaccine administration of COVID-19 for uninsured individuals. The program funding information is as follow:

TESTING The American Rescue Plan Act (ARP) which provided $4.8 billion to reimburse providers for testing the uninsured; the Families First Coronavirus Response Act (FFCRA) Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the FFCRCA (P.L. 116-127) and the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) (PPPHCEA), which each appropriated $1 billion to reimburse health care entities for conducting COVID-19 testing for the uninsured.

TREATMENT & VACCINATION The Provider Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), provided $100 billion in relief funds. The PPPHCEA appropriated an additional $75 billion in relief funds and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act (P.L. 116-260) appropriated another $3 billion. Within the Provider Relief Fund, a portion of the funding from these sources will be used to support healthcare-related expenses attributable to the treatment of uninsured individuals with COVID-19 and vaccination of uninsured individuals. To learn more about the program, visit: https://www.hrsa.gov/CovidUninsuredClaim

This dataset represents the list of health care entities who have agreed to the Terms and Conditions and received claims reimbursement for COVID-19 testing of uninsured individuals, vaccine administration and treatment for uninsured individuals with a COVID-19 diagnosis.

For Provider Relief Fund Data - https://data.cdc.gov/Administrative/HHS-Provider-Relief-Fund/kh8y-3es6

BackgroundPersistent symptoms, described as long COVID or post-COVID-19 condition, pose a potential public health problem. Here, the design and recruitment of the PRIME post-COVID study is described. PRIME post-COVID is a large-scale population-based observational study that aims to improve understanding of the occurrence, risk factors, social, physical, mental, emotional, and socioeconomic impact of post-COVID-19 condition.MethodsAn observational open cohort study was set up, with retrospective and prospective assessments on various health-conditions and health-factors (medical, demographic, social, and behavioral) based on a public health COVID-19 test and by self-report (using online questionnaires in Dutch language). Invited for participation were, as recorded in a public health registry, adults (18 years and older) who were tested for COVID-19 and had a valid Polymerase Chain Reaction (PCR) positive or negative test result, and email address. In November 2021, 61,655 individuals were invited by email to participate, these included all eligible adults who tested PCR positive between 1 June 2020 and 1 November 2021, and a sample of adults who tested negative (2:1), comparable in distribution of age, sex, municipality of residence and year-quarter of testing. New recruitment periods are planned as well. Participants are followed over time by regular follow-up measurements. Data are analyzed using the appropriate data-analyses methods.DiscussionThe PRIME post-COVID study will provide insights into various health-related aspects of post-COVID-19 condition in the context of various stages of the COVID-19 pandemic. Results will inform practical guidance for society, clinical and public health practice for the prevention and care for long-term impact of COVID-19.Trial registration ClinicalTrials.gov identifierNCT05128695.

Data from SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe—Flu Epidemiological Surveillance System), a system for recording cases of SARS in Brazil, including data from COVID-19, maintained by the Ministry of Health (https://opendatasus.saude.gov.br/dataset/bd-srag-2021)

Experimental estimates from three approaches to estimating the percentage of people testing positive for coronavirus (COVID-19) and who experience symptoms four or more weeks after infection, broken down by demographic and viral characteristics, using UK Coronavirus Infection Survey data.